Evidence map›Paper›PMID 29736306›Full record

ArticleAmerican journal of cancer research2018

LMO4 mediates trastuzumab resistance in HER2 positive breast cancer cells.

Keshuo Ding, Zhengsheng Wu, Xiaocan Li, Youjing Sheng, Xiaonan Wang, Sheng Tan

Open access · greenAbstract read
In one paragraph

Article in American journal of cancer research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Keshuo DingDepartment of Pathology, Anhui Medical University Hefei, Anhui, P. R. China.
Zhengsheng WuDepartment of Pathology, Anhui Medical University Hefei, Anhui, P. R. China.
Xiaocan LiDepartment of Pathology, The Second Hospital of Anhui Medical University Hefei, Anhui, P. R. China.
Youjing ShengDepartment of Pathology, Anhui Medical University Hefei, Anhui, P. R. China.
Xiaonan WangLaboratory of Pathogenic Microbiology and Immunology, Anhui Medical University Hefei, Anhui, P. R. China.
Sheng TanLaboratory of Molecular Tumor Pathology, Hefei National Laboratory for Physical Sciences at Microscale and School of Life Sciences, University of Science and Technology of China Hefei, Anhui, P. R. China.
Anhui Medical University · CNHefei National Center for Physical Sciences at Nanoscale · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is the leading cause of cancer-related mortality in women worldwide. Trastuzumab (Herceptin) is an effective antibody drug for HER2 positive breast cancer;

Indexed as

BCL-2breast cancerHER2LMO4trastuzumab resistance

Identifiers

PMID29736306
PMCPMC5934551
OpenAlexW3006441332

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.